E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Refractory colorectal cancer |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10052362 |
E.1.2 | Term | Metastatic colorectal cancer |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate six-month overall survival in refractory, metastatic colorectal cancer patients who receive CP-751,871. |
|
E.2.2 | Secondary objectives of the trial |
To assess the safety and tolerability of multiple intravenous doses of CP 751,871 To evaluate the efficacy of CP-751,871 in terms of progression free survival (PFS) To evaluate the efficacy of CP-751,871 in terms of overall survival (OS) To evaluate the efficacy of CP-751,871 in terms of objective response To collect pharmacokinetics (PK) data of CP 751,871 for future population PK meta-analysis To monitor the immunogenicity of CP 751,871 in terms of producing an anti-drug antibody (ADA) response To explore the feasibility of quantification of circulating tumor cells (CTCs) and that of CTCs expressing the IGF-IR
|
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
Molecular Profiling Supplement dtd 9 August 2007
The primary objective of this additional research component is to collect, store, and use samples to investigate possible associations between genomic and metabonomic variation: • in relation to response to the study drugs, and • in relation to characteristics of the disease/condition under study in the associated clinical trial, and related conditions.
|
|
E.3 | Principal inclusion criteria |
1. Age >18 years 2. Histologically or cytologically confirmed adenocarcinoma arising in the colon or rectum. Histological evaluation (new biopsy) at the time of enrollment is not required. 3. Radiographic evidence of metastatic, progressive disease following standard therapies. Patients in the United States will have been treated previously with, or have a significant known contraindication to, a fluoropyrimidine, irinotecan and oxaliplatin. These patients may or may not have been treated with bevacizumab (Avastin), cetuximab (Erbitux) and/or Panitumumab (Vectibix). Patients outside of the United States will have been treated with, or have a contraindication to, at least 2 prior chemotherapy regimens with whichever drugs are routinely used and available in standard practice in that country. 4. ECOG performance status 0-1. 5. At least three weeks since the last therapy regimen prior to enrollment. Patients must have recovered to NCI CTCAE v3.0< or equal Grade 1 from all acute toxicities (excluding toxicities that are not considered a safety risk by the sponsor and investigator such as alopecia or residual peripheral neuropathy resulting from prior systemic therapy) or the toxicity must be deemed irreversible by the investigator. 6. At least one week since the last radiotherapy. Patients must have recovered from all acute toxicities from radiotherapy. 7. Patients must have adequate hematologic, renal and liver function determined within 14 days prior to enrollment, defined as: a. Absolute neutrophil count > or equal 1.0 x 10e9 cells/L. b. Platelets > or equal 50 x 10e9/L. c. Hemoglobin > or equal 8 g/dL. d. Aspartate and alanine aminotransferases (AST, ALT) < or equal 5 x ULN (upper limit of normal). e. Total serum bilirubin < or equal 2 x ULN f. Serum creatinine < or equal 2.0 mg/dL. 8. Negative pregnancy test within 72 hours of initial dose of CP-751,871 for females of child-bearing potential. Patients must be surgically sterile or postmenopausal females, or must agree to use double barrier contraception during the period of therapy and for 5 months following the last dose of the study drug. Double barrier contraception is defined as male condom plus spermicide in combination with a female condom, diaphragm, or cervical cap; or male condom plus spermicide in combination with an intrauterine device. Within these limits, the specific form of contraception employed is left to the discretion of the patient or the principal investigator. 9. Evidence of a personally signed and dated informed consent indicating that the patient (or a legally acceptable representative) has been informed of all the pertinent aspects of the study. 10. Patients who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures
|
|
E.4 | Principal exclusion criteria |
1. Concomitant treatment with other anti-cancer therapy. 2. Prior anti IGF-IR based investigational therapy. Other investigational therapies (targeted or vaccine), unless otherwise agreed by investigators and sponsor, will require 4 weeks wash-out period or 5 half-lives of the agent, which ever is sooner, before enrollment. 3. Symptomatic brain metastases. Brain metastases stable for <2 weeks before dosing or requiring concurrent steroid therapy or with clinical symptoms. Clinical symptoms suggestive of new brain metastasis within 2 weeks of enrollment. If such evidence exists, new brain metastasis must be ruled out by a CT scan or MRI. Patients that develop brain metastasis during the study will not need to have their treatment interrupted to receive a course of cranial radiation. 4. Major surgery within 4 weeks prior to study enrollment or not fully recovered from side effects of previous procedures. 5. Previous or current malignancies at sites other than basal cell carcinoma, squamous cell skin cancer, or carcinoma in situ of the cervix that has been adequately treated with no evidence of recurrent disease for 12 months. 6. Significant active cardiac disease including: uncontrolled high blood pressure (ie, systolic blood pressure >180 mm Hg, diastolic blood pressure >95 mm Hg), unstable angina, deep venous thrombosis, pulmonary embolism, cerebro vascular attack, valvular disease, congestive heart failure, myocardial infarction (within the previous 6 months), or serious cardiac arrhythmias. 7. Patients who are receiving chronic high-dose systemic immunosuppressive steroid therapy (> or equal 100 mg prednisone per day or >40 mg dexamethasone per day). Use of high-dose corticosteroids within 2 weeks prior to enrollment. 8. Dementia or significantly altered mental status that would limit the understanding or rendering of informed consent and compliance with the requirements of this protocol. 9. Pregnancy or breast feeding. 10. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Six-month overall survival |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Information not present in EudraCT |
E.8.1.2 | Open | Information not present in EudraCT |
E.8.1.3 | Single blind | Information not present in EudraCT |
E.8.1.4 | Double blind | Information not present in EudraCT |
E.8.1.5 | Parallel group | Information not present in EudraCT |
E.8.1.6 | Cross over | Information not present in EudraCT |
E.8.1.7 | Other | Information not present in EudraCT |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 8 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 25 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 25 |
E.8.9.2 | In all countries concerned by the trial days | 0 |